These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22183166)

  • 1. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
    Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1613-5. PubMed ID: 22183166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.
    Snydman DR; Jacobus NV; McDermott LA
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3448-52. PubMed ID: 22391542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
    Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
    Antimicrob Agents Chemother; 2012 May; 56(5):2493-503. PubMed ID: 22290948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
    Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
    Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium.
    Mascio CT; Chesnel L; Thorne G; Silverman JA
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3976-82. PubMed ID: 24798273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.
    Mascio CT; Mortin LI; Howland KT; Van Praagh AD; Zhang S; Arya A; Chuong CL; Kang C; Li T; Silverman JA
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5023-30. PubMed ID: 22802252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
    James GA; Chesnel L; Boegli L; deLancey Pulcini E; Fisher S; Stewart PS
    J Antimicrob Chemother; 2018 Jan; 73(1):102-108. PubMed ID: 29029221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
    Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4872-6. PubMed ID: 23877700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
    Mathur H; O'Connor PM; Hill C; Cotter PD; Ross RP
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2882-6. PubMed ID: 23571539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
    Peláez T; Alcalá L; Alonso R; Rodríguez-Créixems M; García-Lechuz JM; Bouza E
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1647-50. PubMed ID: 12019070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
    Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
    Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of linezolid against Clostridium difficile.
    Peláez T; Alonso R; Pérez C; Alcalá L; Cuevas O; Bouza E
    Antimicrob Agents Chemother; 2002 May; 46(5):1617-8. PubMed ID: 11959617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin.
    O'Connor R; Baines SD; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2008 Oct; 62(4):762-5. PubMed ID: 18606787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin inhibits spore production in Clostridium difficile.
    Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.
    Barbut F; Decré D; Burghoffer B; Lesage D; Delisle F; Lalande V; Delmée M; Avesani V; Sano N; Coudert C; Petit JC
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2607-11. PubMed ID: 10543736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.
    Wong SS; Woo PC; Luk WK; Yuen KY
    Diagn Microbiol Infect Dis; 1999 May; 34(1):1-6. PubMed ID: 10342100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolone resistance and Clostridium difficile, Germany.
    Zaiss NH; Witte W; Nübel U
    Emerg Infect Dis; 2010 Apr; 16(4):675-7. PubMed ID: 20350385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
    Marchese A; Salerno A; Pesce A; Debbia EA; Schito GC
    Chemotherapy; 2000; 46(4):253-66. PubMed ID: 10859431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clostridium difficile bacteremia, Taiwan.
    Lee NY; Huang YT; Hsueh PR; Ko WC
    Emerg Infect Dis; 2010 Aug; 16(8):1204-10. PubMed ID: 20678312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.